Should every patient with MDS get iron chelation – probably yes.

Main Article Content

Kanjaksha Ghosh
Emanuele Angelucci
Federica Pilo
Kinjalka Ghosh

Keywords

Anemia, MDS, Iron Overload, Chelation

Abstract

NA

Downloads

Download data is not yet available.


Abstract 1952
PDF Downloads 508
HTML Downloads 291

References

1. Angelucci E, Urru SA, Pilo F, Piperno A. Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis. 2017 Mar 1;9:e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017.
2.Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br. Jr. Haematol. 2017.177:741-750.
3. Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry .Leuk Res. 2012;36:1067-70.
4. Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N.Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016 ;35:3577-86.
5. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006 ;91:1588-90.
6.Fibach E, Rachmilewitz EASelective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leuk. Res. 2012;36:962-3.
7. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF,Rachmilewitz EA, Hebbel RPDeferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood.199586:2008-13.
8.Cazzola M, Della Porta MG, Malcovati L.The genetic basis of myelodysplasia and its clinical relevance. Blood.2013 ;122:4021-34.
9.Prá D, Franke SI, Henriques JA, Fenech M.Iron and genome stability: an update. Mut. Res. 2012;733:92-9.
10.Gupta M, Madkaikar M, Rao VB, Mishra A, Govindaraj P, Thangaraj K, Ghosh K Mitochondrial DNA variations in myelodysplastic syndrome. Annals . Hematol.2013;92:871-6.
11.Reddy PL, Shetty VT, Dutt D, York A, Dar S, Mundle SD, Allampallam K, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, Suleman S, Kamal SY, Raza A(2002).Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br. Jour. Haematol.2002;116:564-75.
12.Nairz M, Schroll A, Demetz E, Tanncevski I, Theurl I, Weiss G.Ride on the ferrous wheel—The cycle of iron in macrophages in health and disease. Immunobiology, 2014. http//dx.doi.org/10.1016/j.imbio.2014.09.010.

Similar Articles

You may also start an advanced similarity search for this article.